Centre Hospitalier de l'Université de Montréal

ZYUS Life Sciences Initiates Phase 2a Trial for Novel Non-Opioid Cancer Pain Treatment

- ZYUS Life Sciences has activated its first clinical site at Centre Hospitalier de l'Université de Montréal and enrolled the first patient in the Phase 2a UTOPIA-1 trial for Trichomylin® softgel capsules. - The single-arm, proof-of-concept study will investigate the safety and preliminary analgesic efficacy of the cannabinoid-based drug candidate in patients with advanced cancer and moderate to severe cancer-related pain. - Trichomylin® is designed to bridge the treatment gap between conventional therapies such as opioids and NSAIDs, offering a differentiated pharmaceutical approach for cancer pain management. - The trial represents a significant milestone for ZYUS' clinical development program as the company pursues regulatory approval for non-opioid-based pharmaceutical pain management solutions.